Alessandro Zannini

Alessandro Zannini

Auto-generated profile, based on publicly available information

Alessandro Zannini

Laboratorio Nazionale CIB, Area Science Park Padriciano, Trieste, Italy

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 January 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
GSGiovanni Sorrentino
Giovanni Sorrentino
NRNaomi Ruggeri
Naomi Ruggeri
AZAlessandro Zannini
Alessandro Zannini
EIEleonora Ingallina
Eleonora Ingallina
RBRebecca Bertolio
Rebecca Bertolio
GSGiannino Del Sal
Giannino Del Sal
The Hippo pathway is an oncosuppressor signalling cascade that plays a major role in the control of cell growth, tissue homoeostasis and organ size. Dysregulation of the Hippo pathway leads to aberrant activation of the transcription co-activator YAP (Yes-associated protein) that contributes to tumorigenesis in several tissues. Here we identify glucocorticoids (GCs) as hormonal activators of YAP. Stimulation of glucocorticoid receptor (GR) leads to increase of YAP protein levels, nuclear accumulation and transcriptional activity in vitro and in vivo. Mechanistically, we find that GCs increase expression and deposition of fibronectin leading to the focal adhesion-Src pathway stimulation, cytoskeleton-dependent YAP activation and expansion of chemoresistant cancer stem cells. GR activation correlates with YAP activity in human breast cancer and predicts bad prognosis in the basal-like subtype. Our results unveil a novel mechanism of YAP activation in cancer and open the possibility to target GR to prevent cancer stem cells self-renewal and chemoresistance.

16 December 2013 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
ARAlessandra Rustighi
Alessandra Rustighi
AZAlessandro Zannini
Alessandro Zannini
LTLuca Tiberi
Luca Tiberi
RSRoberta Sommaggio
Roberta Sommaggio
SPSilvano Piazza
Silvano Piazza
GSGiannino Del Sal
Giannino Del Sal
Mammary epithelial stem cells are fundamental to maintain tissue integrity. Cancer stem cells (CSCs) are implicated in both treatment resistance and disease relapse, and the molecular bases of their malignant properties are still poorly understood. Here we show that both normal stem cells and CSCs of the breast are controlled by the prolyl‐isomerase Pin1. Mechanistically, following interaction with Pin1, Notch1 and Notch4, key regulators of cell fate, escape from proteasomal degradation by their major ubiquitin‐ligase Fbxw7α. Functionally, we show that Fbxw7α acts as an essential negative regulator of breast CSCs' expansion by restraining Notch activity, but the establishment of a Notch/Pin1 active circuitry opposes this effect, thus promoting breast CSCs self‐renewal, tumor growth and metastasis in vivo . In human breast cancers, despite Fbxw7α expression, high levels of Pin1 sustain Notch signaling, which correlates with poor prognosis. Suppression of Pin1 holds promise in reverting aggressive phenotypes, through CSC exhaustion as well as recovered drug sensitivity carrying relevant implications for therapy of breast cancers.

9 June 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
ECElena Campaner
Elena Campaner
ARAlessandra Rustighi
Alessandra Rustighi
AZAlessandro Zannini
Alessandro Zannini
ACAlberto Cristiani
Alberto Cristiani
SPSilvano Piazza
Silvano Piazza
GSGiannino Del Sal
Giannino Del Sal
The prolyl isomerase PIN1, a critical modifier of multiple signalling pathways, is overexpressed in the majority of cancers and its activity strongly contributes to tumour initiation and progression. Inactivation of PIN1 function conversely curbs tumour growth and cancer stem cell expansion, restores chemosensitivity and blocks metastatic spread, thus providing the rationale for a therapeutic strategy based on PIN1 inhibition. Notwithstanding, potent PIN1 inhibitors are still missing from the arsenal of anti-cancer drugs. By a mechanism-based screening, we have identified a novel covalent PIN1 inhibitor, KPT-6566, able to selectively inhibit PIN1 and target it for degradation. We demonstrate that KPT-6566 covalently binds to the catalytic site of PIN1. This interaction results in the release of a quinone-mimicking drug that generates reactive oxygen species and DNA damage, inducing cell death specifically in cancer cells. Accordingly, KPT-6566 treatment impairs PIN1-dependent cancer phenotypes in vitro and growth of lung metastasis in vivo.

18 December 2017 in Nature Cell Biology
Verified
Journal Article
Open access
PDF file
EIEleonora Ingallina
Eleonora Ingallina
GSGiovanni Sorrentino
Giovanni Sorrentino
RBRebecca Bertolio
Rebecca Bertolio
KLKamil Lisek
Kamil Lisek
AZAlessandro Zannini
Alessandro Zannini
GSGiannino Del Sal
Giannino Del Sal
Tumour-associated p53 missense mutants act as driver oncogenes affecting cancer progression, metastatic potential and drug resistance (gain-of-function)1. Mutant p53 protein stabilization is a prerequisite for gain-of-function manifestation; however, it does not represent an intrinsic property of p53 mutants, but rather requires secondary events2. Moreover, mutant p53 protein levels are often heterogeneous even within the same tumour, raising questions on the mechanisms that control local mutant p53 accumulation in some tumour cells but not in their neighbours2,3. By investigating the cellular pathways that induce protection of mutant p53 from ubiquitin-mediated proteolysis, we found that HDAC6/Hsp90-dependent mutant p53 accumulation is sustained by RhoA geranylgeranylation downstream of the mevalonate pathway, as well as by RhoA- and actin-dependent transduction of mechanical inputs, such as the stiffness of the extracellular environment. Our results provide evidence for an unpredicted layer of mutant p53 regulation that relies on metabolic and mechanical cues.

15 October 2015 in Oncotarget
Verified
Journal Article
Open access
CTCristian Taccioli
Cristian Taccioli
GSGiovanni Sorrentino
Giovanni Sorrentino
AZAlessandro Zannini
Alessandro Zannini
JCJimmy Caroli
Jimmy Caroli
DBDomenico Beneventano
Domenico Beneventano
GSGiannino Del Sal
Giannino Del Sal
MDP, a database linking drug response data to genomic information, identifies dasatinib and statins as a combinatorial strategy to inhibit YAP/TAZ in cancer cells

11 November 2016 in Cell Death & Differentiation
Verified
Journal Article
Closed access
ARAlessandra Rustighi
Alessandra Rustighi
AZAlessandro Zannini
Alessandro Zannini
ECElena Campaner
Elena Campaner
YCYari Ciani
Yari Ciani
SPSilvano Piazza
Silvano Piazza
GSGiannino Del Sal
Giannino Del Sal